Synta Pharmaceuticals Corp.(NASDAQ:SNTA) on Mar. 20 announced presentation of interim results from the ENCHANT-1 trial, a single-arm multi-center Phase 2 proof-of-concept study designed to evaluate ganetespib, the Company’s lead drug candidate, administered as monotherapy for the treatment of metastatic breast cancer. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares after opening at $5.43 moved to $5.51 on last trade day and at the end of the day closed at $5.20.Company price to cash ratio in past twelve months was calculated as 4.37 . Synta Pharmaceuticals Corp.(NASDAQ:SNTA) showed a positive weekly performance of 19.27.
Sinovac Biotech (NYSE:SVA)‘s stock had its “buy” rating restated by equities research analysts at Aegis in a research note issued to investors on Thursday, American Banking News.com reports. Sinovac Biotech Ltd.(NASDAQ:SVA) shares advanced 17.13% in last trading session and ended the day on $8.07. SVA return on equity ratio is recorded as -3.00% and its return on assets is -1.60%. Sinovac Biotech Ltd.(NASDAQ:SVA) yearly performance is 114.63%.
ImmunoCellular Therapeutics, Ltd (NYSE:IMUC) announced that the European Medicines Agency (EMA) has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. Granting of orphan drug status in the EU provides sponsor companies with incentives, including a 10-year period of market exclusivity, access to a centralized review process, trial design assistance and scientific advice during product development, fee reductions, and tax incentives. ImmunoCellular has previously received orphan designation for ICT-107 in glioblastoma in the US. ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) shares moved up 5.15% in last trading session and was closed at $1.43 while trading in range of $1.36 – 1.46 .ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) year to date (YTD) performance is 53.76%.
CEL-SCI Corporation (NYSEAMEX:CVM)’s on Mar. 4 announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina. The trial is already active in dozens of hospitals and clinical centers in 12 countries. 21st Century Oncology is the largest global, physician-led provider of integrated cancer care services, operating 166 treatment centers, with 133 centers in 16 U.S. states and 33 centers in six Latin American countries. CEL-SCI Corporation (NYSEMKT:CVM) weekly performance is 43.31%. On last trading day company shares ended up $1.82. CEL-SCI Corporation (NYSEMKT:CVM) distance from 50-day simple moving average (SMA50) is 65.39%. Analysts mean target price for the company is $7.00.